Heart disease is a leading cause of death, and diabetes makes that risk even higher. For many people, doctors prescribe strong blood thinners to stop clots from forming after heart procedures. Two common drugs in this category are ticagrelor and prasugrel. This study looked at whether one of these drugs works better than the other for patients with diabetes who have had heart stents placed. The results suggest that ticagrelor does not offer a clear advantage over prasugrel for these patients.
The researchers studied 1,800 people across 66 different medical centers. All participants had diabetes and more than one blocked artery in their heart. They had recently undergone a procedure called percutaneous coronary intervention, which is how doctors place stents to open up narrowed arteries. Half of the patients took ticagrelor mixed with low-dose aspirin. The other half took prasugrel mixed with low-dose aspirin. Everyone was followed for one year to see who had serious problems.
The main goal was to see if anyone died, had a heart attack, had a stroke, or suffered major bleeding. The study found that 16.6% of people on ticagrelor had these events, compared to 14.2% of people on prasugrel. That is a difference of 2.33 percentage points. In plain terms, this means about 23 extra people out of every 1,000 had a bad event on ticagrelor compared to prasugrel. The difference was not large, but the study could not prove ticagrelor was safe enough to be considered equal to prasugrel.
Safety was another big concern. The team looked for major bleeding, which can be dangerous. They found that 8.41% of people on ticagrelor had major bleeding, while 7.14% of people on prasugrel did. Again, the numbers were close, with ticagrelor showing a slightly higher rate. However, these differences were not large enough to be called statistically significant. This means the results could have happened by chance, but the study still failed to meet its safety standards.
It is important not to panic or change your medication based on this single study. The numbers show a small difference, not a huge danger. Many factors influence which drug a doctor chooses, including other health issues and past reactions to medicine. This study simply shows that ticagrelor did not prove itself to be noninferior to prasugrel for this specific group. Patients should talk to their doctor about their own history before making any changes to their treatment plan.
For patients with diabetes and multiple blocked arteries, this research means that ticagrelor is not automatically the best choice over prasugrel. Doctors will likely continue to weigh the specific needs of each patient carefully. This study adds to the growing list of evidence that helps doctors make smarter decisions. It reminds us that finding the perfect heart medicine is a complex process that takes time and careful testing.